Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results

NEW YORK (TheStreet) -- Repros Therapeutics  (RPRX) stock is falling 26.09% to $1.77 on heavy volume trading on Tuesday, after the FDA expressed concerns about the company's reproductive drug.

The FDA recommended that Repros conduct an additional Phase 3 study into its enclomiphene drug. The drug is intended to treat a reproductive disorder, known as secondary hypogonadism, in overweight men. 

The FDA also said it was concerned regarding the study's entry criteria, titration and bioanalytical method validation.

"We are disappointed that the FDA has taken this position without the benefit of an advisory committee recommendation," Repros CEO Joseph Podolski said in a statement. "We plan to work closely with the agency to gain more information to determine the appropriate next steps regarding the enclomiphene application."

So far today, 4.13 million shares of Repros have traded, versus its 30-day average of 1.45 million shares.

RPRX Chart

 

RPRX Chart RPRX data by YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%